Instructions for Authors
The Journal of Child and Adolescent Psychopharmacology is published 10 times a year. It focuses on Child and Adolescent Psychopharmacology and those aspects of Child and Adolescent Psychiatry, Neurology, Pediatrics, and the neurosciences that are clearly related to this. The Journal publishes papers encompassing investigative research, treatment techniques, basic sciences, health policy and education, focused reviews and clinical case reports or conferences.
Manuscripts must be submitted online using the following url: http://mc.manuscriptcentral.com/jcap. Please read all the instructions to authors before submitting.
Manuscript Submission and Copyright Agreement Form
The Copyright Agreement form should be submitted once your paper has been accepted for publication. Manuscripts cannot be published without this form. The corresponding author is responsible for obtaining signatures of coauthors. Authors not permitted to release copyright must still return the form signed under the statement of the reason for not releasing the copyright. Upon acceptance of your paper, please fax the Copyright Agreement form to 914-740-2101.
Copyright Agreement Form
Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc. By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal.
Upon acceptance of any manuscript, all authors will receive a follow-up email with instructions on how to complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors’ email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications.
FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM MAY RESULT IN A DELAY OF PUBLICATION.
The corresponding author is responsible for communicating with coauthors to make sure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright.
Deviations from these Instructions for Authors will generally result in a return of the manuscript for correction before review.
The Journal will consider original research papers, brief reports, reviews, and letters to the editors.
Original research articles and brief reports should have a structured Abstract, Introduction, Methods, Results, Discussion, Conclusions, Clinical Significance, Disclosures, Acknowledgments, if needed, References, Tables and Figures, and Legends. One subsection level is allowed.
Brief reports should be no more than 10 manuscript pages including references and disclosures, and no more than 2 tables (or figures). Case reports of 5 or more cases can be submitted as a brief report.
Case Reports of 1-4 cases must be submitted as a Letter to the Editor.
Letters can discuss recent Journal articles, provide new information or commentary, or describe 1-4 cases. Letters that are critical of a published article will be sent to the author(s) for a response. Letters should be limited to 500-750 words (excluding references), no more than 4-5 references, and 1 table or figure if necessary. Letters may be subject to editing, abridgment, and peer review.
Book reviews are usually assigned by the Associate Editor for Book Reviews, but a contributor interested in preparing a review should contact Deborah M. Weisbrot, MD at firstname.lastname@example.org.
MANUSCRIPT SUBMISSION AND REVIEW
A submitted paper (or any essential part) must not be published or simultaneously submitted to other publications prior to its appearance in this Journal (except for abstracts or press reports from scientific meetings).
Submissions to the Journal will undergo peer review. Manuscripts may be edited for clarity, conciseness, grammar, and conformity to Journal style. Authors will receive page proofs before publication.
Authors should include a minimum of 3 to 5 preferred reviewers (with email addresses) whom they think are particularly expert in the subject of their paper. This information should be provided in the preferred reviewer section during the online submission process through manuscript central.
Accepted manuscripts become the permanent property of the Journal, and may be republished elsewhere only with the written permission of the publisher. There are no page charges.
PREPARATION OF MANUSCRIPTS
All text files should be submitted as Word or Word-type files. Do not submit PDFs.
All authors must disclose all institutional or corporate/commercial relationships going back 36 months, or to the time of the data collection if the data were collected longer than 3 years ago, that might pose a conflict of interest. The Journal should also be informed if any conflicts of interest arise after submission and before publication of the paper. Institutional affiliations and funding sources that supported the work (from any grant, funding source, or commercial interest/pharmaceutical company) are to be indicated on the title page.
The Author Disclosure section is to be uploaded along with your manuscript as a separate Word file. The disclosure is required for submission. If the authors have nothing to disclose, state this in the file for each author.
The Disclosures should include all corporate/commercial relationships that might pose a conflict of interest, e.g., all of the authors' relationshps with all pharmaceutical companies. This includes such things as all consultantships, honoraria, stock ownership, gifts, free or reimbursed travel/ vacations, equity interests, arrangements regarding patents or other vested interests, etc. (not just those immediately related to this specific paper or to the pharmaceutical company sponsoring the submitted paper). If a specific author has no financial relationships with any pharmaceutical company, it must be so stated in the Disclosure section. If the study was supported by a pharmaceutical company, it must be stated in the Disclosure section who analyzed the data and who wrote the paper (the authors or a medical writer). Papers submitted without an Author Disclosure section will not be reviewed.
On the first page, give the full title of the article, full name(s) and highest academic degree(s) of all author(s), the name of the department and institution where the work was done, and other institutional affiliation(s) and title(s). State the names and affiliations of statistical consultants. Support received from any grant, funding source, or commercial in-terest should be indicated. Also, give name, address, telephone, and email address of the corresponding author and of the author who will receive requests for reprints. Provide a running title that is less than 45 characters. Include an abstract. Please number all pages consecutively.
Whenever possible, the titles of papers should provide specific information rather than merely suggest a general topic. Many readers who scan the medical literature in indexing sources see only the titles, and should receive information by scanning. Titles in the Journal should be self-explanatory and self-contained. Rather than a title such as "Conduct Disorder and ADHD," use "Conduct Disorder Is Present in 70% of Children with Attention-Deficit/Hyperactivity Disorder." Please avoid two-part titles and abbreviations.
All submissions, except letters, must be accompanied by a structured abstract of less than 300 words. The abstract must have the following four sections: Objectives, Methods, Results, and Conclusion. The abstract should be fully understood on its own, without any reference to the text itself. Statements that give generalized accounts, such as "Implications will be discussed," are not helpful: Indicate concisely what are seen as the most important implications.
Tables, Figures, and Illustrations
Each table and figure should be able to stand alone; i.e., contain all explanatory information in the caption. A title and a double-spaced caption should be provided for each table and figure. All abbreviations must be explained in each figure caption or table footnote. If a figure consists of more than one part, individual parts should have similar dimensions. Tables and figures should be numbered in order of appearance, using Arabic numerals. A list of all tables and figures should be attached at the end of the manuscript.
Each table and figure should appear on a separate page. If a table exceeds one page, then repeat the title on the next page followed by "continued." When percentages are stated, the absolute numbers must also be indicated.
Figures should be professionally drawn and photographed. Figures that do not meet publishing standards will be returned for revision. Lettering and symbols should be clear and large enough to remain legible after the figure has been reduced. Electron photomicrographs should contain internal scale markers.
Color illustrations can be printed in the Journal with a subsidy from the author(s). If you do not wish to pay for color figures, please upload black and white figures when you submit. If photographs of patients are used, either the subjects should not be identifiable or written permission to publish the photograph (for children, from both parents) must accompany the submission. Permission forms are available from the Editors.
All images must be submitted as high-resolution jpeg or tif files. (Do not use gif or pdf format.)
In research involving statistical analysis, please include the following: (a) the hypotheses in clearly stated form, (b) the statistical tests used, cited by name, for each data set, (c) the use of either one-tailed or two-tailed tests, and (d) the test value, degree(s) of freedom, and probability for every significant and important nonsignificant result. Use standard deviations rather than standard errors of the mean. For novel or not well-known tests, provide a citation.
Each original research article, review, or brief report should include a "Clinical Significance," just before the Author Disclosure statement. This section requires one brief paragraph that will communicate the clinical importance of the work, and its relevancy to the scientific community, in a few short sentences.
Authors maintain responsibility for the accuracy of their citations. Text citations will appear preferably at the end of sentences, and will indicate first (A 1990), first and second (A and B 1990), or first plus (A plus all coauthors 1990) authors, with year of publication and without a comma. Citations in the reference section should list all coauthors (et al. is not permitted in the reference list), be alphabetized rather than numbered, and multiple citations to one author should be placed in chronological sequence; the list should be double spaced, with each reference separated by a single line of space. Any references published in a foreign language should be followed by an English translation in brackets. Do not indicate issue numbers unless issues are not sequentially paginated. Credit for figures and illustrations should be given in captions. Personal communications, unpublished data, and manuscripts "in preparation" or "submitted for publication" may be incorporated into the text but not in the reference list. Abbreviations will follow the style of Medline. Please follow the style of these examples:
Riddle MA, Hardin MT, King R, Scahill L, Woolston
JL: Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 29:45-48, 1990.
Courchesne E, Yeung-Courchesne R: Event-related brain potentials. In: Assessment and Diagnosis in Child Psy-chopathology. Edited by Rutter M, Tuma AH, Lann IS. New York, Guilford Press, 1988, pp 264-299.
Adams GR, Montemayor R, Gullotta TP (eds): Biology of Adolescent Behavior and Development. Newbury Park (California), Sage Publications, 1989.
Geller B: A double-blind placebo-controlled study of nortriptyline in adolescents with major depression. Washington (DC), National Institute of Mental Health, New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, 1989 (abstract).
Abbreviations and Medication Names
Weights, heights, and other measurements should be in the metric system. When an abbreviation or acronym is first used in the abstract and in the text, it must be spelled out in full and followed by the abbreviation in parentheses. When an abbreviation or acronym is used in each table and figure, it should be spelled out in full in the table footnote or figure citation. For standard abbreviations, consult the Style Manual for Biologic Journals, 4th edition (American Institute of Biological Sciences, 1401 Wilson Blvd, Arlington, VA 22209).
Identify medications by generic name. For materials and devices, describe by nonproprietary name, and then indicate (in parentheses) brand name, manufacturer's name, city, state, and country.
Materials taken from other sources must be accompanied by written statements from both author and publisher giving permission for reproduction to the Journal. If clearance is also required by the author's institution, these statements should be provided with the manuscript. For papers in press, unpublished data, and personal communications, submit written permission from the first author along with the manuscript.
Strict anonymity of patients must be maintained. Do not use actual names, initials, dates, or hospital numbers. In describing the personal characteristics of a patient, disguise any potentially identifying information. [The only exception is a photograph of an identifiable patient, for whom written permission for publication has been obtained.]
Informed Consent and Assent
For clinical reports, an explicit description of the informed consent procedures involving both parents, as well as the assent provided by younger adolescents and children, is required in the Methods section. Agreement is required both for consent to research and permission to publish.
Human or Animal Experimentation
Reports of research involving experimental subjects should be accompanied by a statement indicating approval by the Institutional Review Board (or Institutional Animal Care and Use Committee).
Thanking individuals involved in the scientific or technical aspects of manuscript preparation should not exceed four typed lines.
Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
The originality and accuracy of data, statements, and opinions in the Journal are the responsibility and liability of the individual contributors (and advertisers). These statements do not necessarily represent the views of the editors, the publisher, or the Journal.
The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801-5215. Telephone: (914) 740-2100; fax: (914) 740-2101; e-mail: email@example.com internet: www.liebertpub.com
The views, opinions, findings, conclusions and recommendations set forth in any
Journal article are solely those of the authors of those articles and do not necessarily
reflect the views, policy or position of the Journal, its Publisher, its editorial
staff or any affiliated Societies and should not be attributed to any of them.